JP7335232B2 - 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物 - Google Patents

安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物 Download PDF

Info

Publication number
JP7335232B2
JP7335232B2 JP2020517288A JP2020517288A JP7335232B2 JP 7335232 B2 JP7335232 B2 JP 7335232B2 JP 2020517288 A JP2020517288 A JP 2020517288A JP 2020517288 A JP2020517288 A JP 2020517288A JP 7335232 B2 JP7335232 B2 JP 7335232B2
Authority
JP
Japan
Prior art keywords
aspirin
water
asa
tba
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522577A5 (enExample
JP2020522577A (ja
Inventor
アール． パレプ，ナゲシュ
Original Assignee
ローシャン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローシャン ファーマシューティカルズ，インコーポレーテッド filed Critical ローシャン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2020522577A publication Critical patent/JP2020522577A/ja
Publication of JP2020522577A5 publication Critical patent/JP2020522577A5/ja
Priority to JP2023096643A priority Critical patent/JP2023116657A/ja
Application granted granted Critical
Publication of JP7335232B2 publication Critical patent/JP7335232B2/ja
Priority to JP2025112118A priority patent/JP2025163015A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020517288A 2017-05-30 2018-05-29 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物 Active JP7335232B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023096643A JP2023116657A (ja) 2017-05-30 2023-06-13 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP2025112118A JP2025163015A (ja) 2017-05-30 2025-07-02 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512367P 2017-05-30 2017-05-30
US62/512,367 2017-05-30
PCT/US2018/034866 WO2018222583A1 (en) 2017-05-30 2018-05-29 In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023096643A Division JP2023116657A (ja) 2017-05-30 2023-06-13 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物

Publications (3)

Publication Number Publication Date
JP2020522577A JP2020522577A (ja) 2020-07-30
JP2020522577A5 JP2020522577A5 (enExample) 2021-08-12
JP7335232B2 true JP7335232B2 (ja) 2023-08-29

Family

ID=64455035

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517288A Active JP7335232B2 (ja) 2017-05-30 2018-05-29 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP2023096643A Pending JP2023116657A (ja) 2017-05-30 2023-06-13 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP2025112118A Pending JP2025163015A (ja) 2017-05-30 2025-07-02 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023096643A Pending JP2023116657A (ja) 2017-05-30 2023-06-13 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP2025112118A Pending JP2025163015A (ja) 2017-05-30 2025-07-02 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物

Country Status (6)

Country Link
US (4) US11096949B2 (enExample)
EP (1) EP3630120A4 (enExample)
JP (3) JP7335232B2 (enExample)
CN (2) CN117379443A (enExample)
CA (1) CA3064012A1 (enExample)
WO (1) WO2018222583A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379443A (zh) * 2017-05-30 2024-01-12 罗山制药股份有限公司 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物
US11793748B1 (en) 2019-04-05 2023-10-24 Good Health, Llc Pharmaceutical compositions of aspirin for parenteral administration
WO2023198294A1 (en) 2022-04-14 2023-10-19 Hyloris Developments Sa Acetyl salicylic acid composition for intravenous administration, its storage, production and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542316A (ja) 2005-06-02 2008-11-27 バイエル・ヘルスケア・アクチェンゲゼルシャフト ｏ−アセチルサリチル酸の塩基性アミノ酸との塩およびグリシンの安定な活性化合物複合体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB912894A (en) * 1959-11-02 1962-12-12 Guy Leopold Van Moorleghem Method for the preparing a solution of aspirin for injection and product obtained thereby
GB993682A (en) * 1962-07-09 1965-06-02 Haessle Ab Salts of acetylsalicylic acid, their production and pharmaceutical preparations containing them
JPS4856815A (enExample) * 1971-11-13 1973-08-09
US4117603A (en) * 1976-12-28 1978-10-03 Smith Walton J High vacuum freeze-drying
CA1131245A (en) 1978-07-12 1982-09-07 Walton J. Smith Freeze dried pharmaceuticals
JPS5610110A (en) 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
US4975269A (en) 1989-07-31 1990-12-04 Leonard Chavkin Shelf stable aspirin solutions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
WO1999003474A1 (de) 1997-07-15 1999-01-28 Walter Burghart Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen
EP1094819A1 (en) * 1998-07-09 2001-05-02 Alexander Galat Injectable sodium acetylsalicylate composition and method
DE10011032A1 (de) * 2000-03-07 2001-09-13 Bayer Ag Acetylsalicylsäure-Lösungen
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
ES2189639B1 (es) * 2001-05-22 2005-02-01 Jesus Angel Hernandez Cordon Composicion acuosa que contiene acido acetilsalicilico.
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
WO2005039464A1 (en) * 2003-10-10 2005-05-06 Oryxe Transdermal high and low molecular weight compounds
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US20080096947A1 (en) 2004-10-15 2008-04-24 Heidelberg Pharma Ag Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7202229B1 (en) 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US8481600B2 (en) * 2007-05-16 2013-07-09 Academic Pharmaceuticals, Inc. Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral administration for the treatment of cardiovascular and other disease states
DE202007007241U1 (de) * 2007-05-21 2007-09-20 Temmen Gmbh Krebsprävention an Säugern durch Aktivierung embryonaler Zellen im Verlaufe der ontogenetischen Entwicklung mit Hilfe von Zellwachstumsregulatoren (Auxine) in Kombination mit einem Trägerstoff aus Phospholipiden und Pflanzenölen
CN102480945A (zh) * 2009-06-03 2012-05-30 艾克斯特克有限责任公司 皮肤处理组合物
EA021588B1 (ru) 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
KR20120113267A (ko) * 2010-01-15 2012-10-12 리쎄라 인코오포레이티드 동결건조 케이크 제제
RO128007A2 (ro) * 2011-06-01 2012-12-28 Institutul Naţional De Cercetare-Dezvoltare Pentru Tehnologii Izotopice Şi Moleculare Procedeu de obţinere a ansamblurilor funcţionale micro/nano-structurate de chitosan şi substanţe active antiinflamatoare prin autoasamblare simultană
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
EP3005877B1 (en) * 2013-05-30 2019-08-28 Haier Group Corporation Vegetable freshness-preservation and growing case and ecological vegetable freshness-preservation method
BR112015032262A2 (pt) * 2013-06-28 2017-07-25 Rexahn Pharmaceuticals Inc composições de nanopartículas e formulações de compostos de piperazina
US9553620B2 (en) * 2014-07-16 2017-01-24 Raytheon Company Signal detection and characterization
CN104546678A (zh) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 一种阿司匹林组合物冻干片及其制备方法
CN104546680A (zh) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 一种阿司匹林组合物冻干片及其制备方法
DE102015002709A1 (de) 2015-03-04 2016-09-08 Cfso Gmbh Neue Verwendung von Acetylsalicylsäure und einem Derivat davon
CN117379443A (zh) * 2017-05-30 2024-01-12 罗山制药股份有限公司 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542316A (ja) 2005-06-02 2008-11-27 バイエル・ヘルスケア・アクチェンゲゼルシャフト ｏ−アセチルサリチル酸の塩基性アミノ酸との塩およびグリシンの安定な活性化合物複合体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEM. PHARM. BULL，2002年，Vol.50, No.5，pp.567-570，https://www.jstage.jst.go.jp/article/cpb/50/5/50_5_567/_pdf/-char/en
CRYSTAL GROWTH & DESIGN，2013年，Vol.13, No.10，pp.4599-4606
European Journal of Pharmaceutical Sciences，2002年，Vol.15,No.2，pp.115-133
パーソナルアハンドブック ，2016年，pp.647-648
新・薬剤学総論（改訂第３版） Introduction to Modern Pharmaceutics ，第1版，株式会社南江堂，pp.319-343

Also Published As

Publication number Publication date
CN117379443A (zh) 2024-01-12
US11096949B2 (en) 2021-08-24
WO2018222583A1 (en) 2018-12-06
CN110996965A (zh) 2020-04-10
JP2023116657A (ja) 2023-08-22
CA3064012A1 (en) 2018-12-06
US10959955B1 (en) 2021-03-30
US20220409636A1 (en) 2022-12-29
JP2020522577A (ja) 2020-07-30
US12048708B2 (en) 2024-07-30
JP2025163015A (ja) 2025-10-28
EP3630120A1 (en) 2020-04-08
EP3630120A4 (en) 2021-01-13
US11911400B1 (en) 2024-02-27
US20200188417A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
JP2023116657A (ja) 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP3357376B2 (ja) 安定な凍結乾燥医薬処方
KR100773658B1 (ko) Ｏ-아세틸살리실산의 염기성 아미노산과의 안정한 염
JP3576180B2 (ja) 改良イフォスファミド凍結乾燥組成物
JPH08500104A (ja) 結晶質アミホスチン組成物及びその調製方法並びに使用
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP2007526329A (ja) 賦形剤の結晶化を改善するための凍結乾燥法
JP6942182B2 (ja) カルグルミン酸を含有する非経口的薬剤配合物
ES2286177T3 (es) Procedimiento para la preparacion de piroxicam: compuestos de inclusion de betaciclodextrina.
ES2657944T3 (es) Sal estable de arginina de pemetrexed y composiciones que la comprenden
JP6165986B2 (ja) ボルテゾミブを含む医薬組成物
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
US5972912A (en) Method for lyophilizing ifosfamide
WO2007075452A2 (en) Lyophilized compositions of a triazolopyrimidine compound
AU2018294561B2 (en) New oral formulations of belinostat
WO2001047542A1 (en) Vancomycin preparations
KR20250134679A (ko) 라니피브라노르 제형
CN118613251A (zh) 包含异𫫇唑啉衍生物的注射制剂及其制备方法
CN1165305C (zh) 尼莫地平冻干组合物
CN108289840A (zh) 用于静脉内注射Danirixin的制剂
WO2011137459A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
CN103037848A (zh) 氟吡汀的可注射剂型

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230817

R150 Certificate of patent or registration of utility model

Ref document number: 7335232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150